GAMMA Investing’s Heron Therapeutics HRTX Stock Holding History

GAMMA Investing’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-889	Closed	-$1.16K	–	4174
2025 Q4	$1.16K	Buy	+889	New	+$1.1K	﹤0.01%	3748

Other funds holding HRTX

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

GAMMA Investing's HRTX Position: Q1 2026 in Review

GAMMA Investing sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 889 shares — an estimated $1.16K sold.

GAMMA Investing first reported a position in HRTX in Q4 2025 and held it in 1 quarter. The position peaked at $1.16K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

GAMMA Investing reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
GAMMA Investing sold 889 Heron Therapeutics shares in Q1 2026, an estimated $1.16K.
GAMMA Investing first reported a position in Heron Therapeutics in Q4 2025 and held it in 1 quarter.
GAMMA Investing's Heron Therapeutics position peaked at $1.16K in Q4 2025.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.